STOP-Uveitis研究主要(第6个月)结局:评估托珠单抗治疗非感染性葡萄膜炎的安全性、耐受性和疗效
STOP-Uveitis是一项在美国5个中心开展的随机、开放标签、多中心临床试验,37例非感染性中间型、后型或全葡萄膜炎患者按1:1随机接受每4周静脉输注托珠单抗4 mg/kg或8 mg/kg至第6个月。第6个月时,有2步玻璃体混浊下降潜力的患者中43.5%实现2步下降(组1为40%,组2为46.1%);黄斑中心凹厚度平均变化为-83.88±136.1 μm(组1为-131.5±41.56 μm,组2为-38.92±13.7 μm);视力平均变化为+8.22±11.83 ETDRS字母(组1为10.9±14.6,组2为5.5±7.8)。重复输注托珠单抗耐受良好,两种剂量均能改善视力并降低玻璃体混浊和黄斑中心凹厚度。
要点
- 37例非感染性葡萄膜炎患者随机接受托珠单抗4 mg/kg或8 mg/kg每4周静脉输注至第6个月。
- 第6个月有2步玻璃体混浊下降潜力的患者中43.5%实现2步下降(组1为40%,组2为46.1%)。
- 第6个月黄斑中心凹厚度平均变化为-83.88±136.1 μm,视力平均变化为+8.22±11.83 ETDRS字母。
核心结论
- 重复静脉给予托珠单抗耐受良好,4 mg/kg和8 mg/kg两种剂量均能改善非感染性中间型、后型或全葡萄膜炎患眼的视力并降低玻璃体混浊和黄斑中心凹厚度。
研究设计与样本
- 随机、对照、多中心临床试验,在美国5个临床中心开展。
- 37例非感染性葡萄膜炎患者按1:1随机分为两组,组1接受托珠单抗4 mg/kg静脉输注,组2接受8 mg/kg静脉输注,两组均每4周输注一次至第6个月(主要终点)。
- 主要结局指标为截至第6个月全身和眼部不良事件的发生率和严重程度,次要结局指标包括第6个月视力、玻璃体混浊和黄斑中心凹厚度的平均变化。
主要发现
- 第6个月,有2步玻璃体混浊下降潜力的患者中43.5%实现2步下降(组1为40%,组2为46.1%)。
- 第6个月黄斑中心凹厚度平均变化为-83.88±136.1 μm(组1为-131.5±41.56 μm,组2为-38.92±13.7 μm)。
- 第6个月视力平均变化为+8.22±11.83 ETDRS字母(组1为10.9±14.6,组2为5.5±7.8)。
- 重复输注托珠单抗耐受良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the primary endpoint analyses of the safety and efficacy of 2 different doses of intravenous (IV) infusions of tocilizumab (TCZ), an IL-6 inhibitor, in eyes with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. DESIGN: Randomized, controlled, multicenter clinical trial. METHODS: STOP-Uveitis is a randomized, open-label safety, efficacy, and bioactivity clinical trial conducted at 5 clinical centers across the United States. The study evaluated the role of TCZ in patients with noninfectious uveitis (NIU). Thirty-seven patients with NIU were randomized into one of 2 treatment groups in a ratio of 1:1. Group 1 received IV infusions of 4 mg/kg TCZ and group 2 received IV infusions of 8 mg/kg TCZ. Infusions were given every 4 weeks in both groups until month 6 (primary endpoint). Primary outcome measure was incidence and severity of systemic and ocular adverse events through month 6. Secondary outcome measures included mean change in visual acuity (VA), vitreous haze (VH), and central macular thickness (CMT) at month 6. RESULTS: A total of 37 patients were randomized in the study. At month 6, 43.5% of patients who had the potential for a 2-step decrease in VH demonstrated a 2-step decrease (40% in Group 1 and 46.1% in Group 2). Mean change in CMT was -83.88 ± 136.1 μm at month 6 (-131.5 ± 41.56 μm in Group 1 and -38.92 ± 13.7 μm in Group 2). Mean change in VA was +8.22 ± 11.83 ETDRS letters at month 6 (10.9 ± 14.6 in Group 1 and 5.5 ± 7.8 in Group 2). Repeated infusions of TCZ were well tolerated. CONCLUSIONS: Repeated IV administrations of TCZ are well tolerated. TCZ (both 4 and 8 mg/kg) is effective in improving VA and reducing VH and CMT in eyes with noninfectious intermediate uveitis, posterior uveitis, and panuveitis.
引用
- Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. Am J Ophthalmol. 2017. PMID: 28887113. doi:10.1016/j.ajo.2017.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。